PERCEIVED BENEFITS OF TREATMENTS OF ALZHEIMER’S DISEASE AND RELATED DEMENTIAS FOR COST-EFFECTIVENESS ESTIMATES

Faika Zanjani, Madeline McIntyre, Tracey Gendron, Eline van den Broek-Altenburg · 2024

Read PERCEIVED BENEFITS OF TREATMENTS OF ALZHEIMER’S DISEASE AND RELATED DEMENTIAS FOR COST-EFFECTIVENESS ESTIMATES by Faika Zanjani, Madeline McIntyre, Tracey Gendron, Eline van den Broek-Altenburg (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11692495.txt.

Description

Faika Zanjani and co-authors ask what people value in new dementia drugs beyond extra healthy years. Their 2024 study runs 12 focus groups with people at risk of Alzheimer disease and with caregivers. Standard cost studies count only quality-adjusted life years, which may miss much of what families care about.

Hope and the value of having options ranked high with the groups. Cost and side effects mattered, but so did the strain on family life. Many felt lost in a health system they saw as poorly joined up and short on specialists. The authors say cost studies that skip hope under-price these drugs. Access snags may still blunt their worth.

Catalog record

CREATORFaika Zanjani, Madeline McIntyre, Tracey Gendron, Eline van den Broek-Altenburg
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11692495

Browse the full library · About the Tower of Babel